33050-32-7

Basic information

• Product Name: 6-CHLORO[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3(2H)-ONE
• Synonyms: 6-CHLORO[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3(2H)-ONE
• CAS NO: 33050-32-7
• Molecular Formula: C₅H₃ClN₄O
• Molecular Weight: 170.56
• Mol File: 33050-32-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 265-275°C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.95g/cm³
• Refractive Index: 1.849
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: DMSO (Sparingly), Methanol (Slightly, Sonicated)
• CAS DataBase Reference: 6-CHLORO[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3(2H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3(2H)-ONE(33050-32-7)
• EPA Substance Registry System: 6-CHLORO[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3(2H)-ONE(33050-32-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 33050-32-7(Hazardous Substances Data)

Usage

Uses

6-Chloro[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one can be used in pharmaceutical composition to treat knee osteoarthritis.

InChI:InChI=1/C5H3ClN4O/c6-3-1-2-4-7-8-5(11)10(4)9-3/h1-2H,(H,8,11)

Upstream product

• 141-30-0 3,6-dichlorpyridazine 
• 563-41-7 semicarbazide hydrochloride 
• 62082-13-7 3-chloro-6-hydrazino-6H-pyridazine-1-carboxylic acid ethyl ester 

Downstream Products

• 263402-18-2 6-[3-[4-(diphenylmethoxy)piperidino]propylamino][1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one 
• 1609565-39-0 4-fluoro-N-(5-(3-(3-hydroxy-3-methylbut-1-yn-1-yl)-[1,2,4]-triazolo[4,3-b]pyridazin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 

Relevant articles and documents

Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family

Bromodomain and extra-terminal (BET) is a promising therapeutic target for various hematologic cancers. We used the BRD4 inhibitor compound 13 as a lead compound to develop a variety of compounds, and we introduced diverse groups into the position of the compound 13 orienting toward the ZA channel. A series of compounds (14–23, 38–41, 43, 47–49) bearing triazolopyridazine motif exhibited remarkable BRD4 protein inhibitory activities. Among them, compound 39 inhibited BRD4(BD1) protein with an IC50 of 0.003 μM was superior to lead compound 13. Meanwhile, compound 39 possess activity, IC50 = 2.1 μM, in antiproliferation activity against U266 cancer cells. On the other hand, compound 39 could arrest tumor cells into the G0/G1 phase and induce apoptosis, which was consistent with its results in inhibiting cell proliferation. Biological and biochemical data suggest that BRD4 protein might be a therapeutic target and that compound 39 is an excellent lead compound for further development.

HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE

The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.